Want to see BLTE full AI Analyst Report?
BLTE Stock Chart & Stats
$153.36
$5.07(3.31%)
At close: 4:00 PM EDT
$153.36
$5.07(3.31%)
Day’s Range― - ―
52-Week Range$60.00 - $200.00
Previous Close$157.3
Volume136.54K
Average Volume (3M)64.23K
Market Cap
$6.36B
Enterprise Value$5.30K
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 12, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$216.20Price Target Upside40.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.28
Revenue Forecast (FY)$22.50M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & LiquidityA near-$800M cash base and minimal debt provide durable financial flexibility to fund late-stage development, NDA completion, and an initial commercial launch. This large runway materially reduces near-term financing risk and supports multi-year program execution and commercialization preparation.
Regulatory Progress: NDA Rolling SubmissionReceiving the Phase 3 report and starting a rolling NDA represent a structural shift from pure development to regulatory review and potential approval. This advances the company toward commercialization, creates clearer timelines for milestone realization, and increases long-term product optionality versus pre-filing peers.
Commercial Buildout & Manufacturing ReadinessActive hires across commercial, market access, and medical affairs plus simple small-molecule manufacturing materially de-risks launch execution. Building capabilities now shortens time-to-market after approval and improves odds of capturing early specialist adoption in a rare-disease niche.
Bears Say
High And Worsening Cash BurnConsistently negative and accelerating operating cash flow signals sustained funding needs even as the company transitions toward commercialization. Large ongoing cash burn increases reliance on existing cash or future financing, affecting strategic optionality beyond current runway if commercialization or approvals face delays.
Pre-revenue With Widening LossesAbsent product revenues, expanding R&D and SG&A drive materially wider losses, meaning capital is consumed to reach approval rather than generate returns. This structural operating deficit will persist until commercial sales scale, pressuring returns on equity and necessitating disciplined capital deployment.
Clinical And Regulatory Uncertainty On Key EndpointsRegulatory advice to complete pivotal follow-up and an uncertain GA interim readout create persistent approval timing risk. Potential additional data requirements or delayed readouts can extend development timelines, increase spend, and materially affect the pace of revenue generation and commercial planning.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $60.00 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.36B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on May 20, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.635 by $0.295.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.78.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 39,965,313 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.635. Following the earnings report the stock price went up 2.62%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$216.20 (40.98% Upside)
$216.20 (40.98% Upside)
Hedge Fund Trend
Decreased
By 584.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
394.07%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program and commercial progress—Phase 3 report received, NDA rolling submission underway, Dragon 2 enrollment completed, substantial commercial hires, and a robust cash position (~$799M). However, the company is incurring sharply higher R&D and SG&A expenses, net losses widened materially, and several clinical and regulatory uncertainties remain (GA interim unknown; FDA guidance requires completion of Dragon 1 at 2 years). On balance the positive development and financial runway outweigh the near‑term expense and uncertainty headwinds.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$216.20
▲(40.98% Upside)
Technical Analysis
PTC Therapeutics
―
Travere Therapeutics
―
Xenon
―
Rhythm Pharmaceuticals
―
Mirum Pharmaceuticals
―
Ownership Overview
1.03% Insiders
0.81% Mutual Funds
0.03% Other Institutional Investors
98.05% Public Companies and
Individual Investors